Independent Coverage of the 2007 San Antonio Breast Cancer Symposium - CME

Bone Loss and Bone Metastases in Breast Cancer: A Report from the 2007 San Antonio Breast Cancer Symposium (SABCS) - CME

Immunostimulant MTP Improves Survival in Pediatric Osteosarcoma (3/5/2008)
Researchers affiliated with the Children’s Oncology Group have shown that the addition of muramyl tripeptide (MTP) to chemotherapy improves survival in patients with osteosarcoma. The details of this study appeared in the February 1, 2008 issue of the Journal of Clinical Oncology.

Not Approvable Letter for Mifamurtide (9/19/2007)
IDM Pharma, Inc. has received a not approvable letter from the United States Food and Drug Administration (FDA) for their investigational drug mifamurtide (L-MTP-PE) – formerly Junovan – for the treatment of osteosarcoma.  

Neoadjuvant Chemotherapy Effective for Older Patients with Osteosarcoma (8/6/2007)
Researchers from Italy have reported that neoadjuvant chemotherapy improves prognosis and reduces amputations in patients over 40 years of age with localized osteosarcoma of the extremity. The details of this study appeared in the June, 2007 issue of Acta Orthopedica.

Radium-223 Effective for Hormone Refractory Prostate Cancer and Bone Metastases (7/9/2007)
Researchers from Sweden and Norway have reported that bone-targeted Radium-223 was associated with significant palliation in patients with hormone refractory prostate cancer (HRPC). The details of this randomized trial appeared in the July, 2007 issue of Lancet Oncology. 

High-Dose Therapy Confirmed as Effective for Refractory Ewing’s Sarcoma (8/28/2006)
Researchers from the United Kingdom have reported that high-dose chemotherapy with autologous peripheral blood stem cell support results in a five-year event-free survival (EFS) of 38% in patients with relapsed or refractory Ewing’s sarcoma.